More Percheron Therapeutics Limited news
Percheron Therapeutics LimitedASX: PER

ATL1102 for MS Phase IIb Investigational New Drug Submission

Apr 23, 2017 at 11:20 PM EDT · Issued by Percheron Therapeutics Limited

Filed with ASX · Apr 23, 2017 at 11:20 PM EDT · 1 page · English

On 6ix: 6ix.com/news/atl1102-for-ms-phase-iib-investigational-new-drug-submission

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

  • Market and Technology UpdateMar 23, 2017
  • ATL1103 Patent UpdateFeb 23, 2017
  • ATL1102 for MS - Progress UpdateFeb 15, 2017
  • Appendix 3CDec 7, 2016
  • Bonus and New Options Offer ProspectusNov 28, 2016

Later from Percheron Therapeutics

  • ATL1103 UpdateMay 17, 2017
  • Positive effects with ATL1102 on MS Black Hole lesionsJun 15, 2017
  • ATL1102 for MS Phase IIb IND submitted to the FDAJun 25, 2017
  • Antisense Therapeutics to enter clincial development in DMDJun 26, 2017
  • ATL1102 for Multiple Sclerosis Phase IIb trial UpdateJul 26, 2017
All Percheron Therapeutics news releases↗

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer